Trial Profile
A Study to Evaluate the Efficacy of Combination of Bevacizumab + Liposomal Doxorubicin with mTOR Inhibitors Temsirolimus or Everolimus in Patients With Advanced Triple Negative Breast Cancer (TNBC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Feb 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Doxorubicin liposomal (Primary) ; Everolimus (Primary) ; Temsirolimus (Primary)
- Indications Advanced breast cancer; Breast cancer; Triple negative breast cancer
- Focus Proof of concept; Therapeutic Use
- 10 Feb 2016 New trial record
- 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium